Triple Negative Breast Neoplasms
📧 Sign up to get email alerts when something new happens for Triple Negative Breast Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-28EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC
Trodelvy (sacituzumab govitecan) has been authorised by the EMA for breast cancer indications including triple-negative breast cancer.
-
EMA approval · 2026-07-16EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC
EMA authorised Trodelvy (sacituzumab govitecan) for breast neoplasms, including triple negative breast neoplasms, with Gilead Sciences Irela…
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: A Study of AK-01 (LY3295668) in Solid Tumors [Phase 1, Phase 2]
A two-phase clinical trial evaluating AK-01 (LY3295668) in solid tumors has completed phases 1 and 2 with posted results.
-
CLINICAL_TRIALS trial_result · 2017-01-13Clinical Trial Update: A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations [Phase 2]
Phase 2 trial evaluating PF-03084014 in advanced breast cancer with/without notch alterations; terminated with results posted in 2017.